Table 2 Prognostic factors for OS as determined by multivariate Cox proportional hazards regression model.
Variables | Mortality in LS-SCLC | |||
|---|---|---|---|---|
Univariate (N = 87) | Multivariate (N = 86) | |||
HR (95% CI) | p-value | HR (95% CI) | P-values | |
Male sex (vs. female) | 0.797 (0.39, 1.62) | 0.5306 | ||
Age, years | 1.014 (0.98, 1.05) | 0.3964 | ||
BMI, kg/m2 | 0.965 (0.89, 1.05) | 0.4201 | ||
Smoking, ever-smoker (vs. never-smoker) | 1.690 (0.23, 12.25) | 0.6035 | ||
Radiotherapy dose (Gy), ≥ 60 (vs. 45 ≤ < 60) | 0.532 (0.32, 0.90) | 0.0185 | ||
ECOG PS ≥ 1 (vs. 0) | 1.273 (0.76, 2.12) | 0.3560 | 1.595 (0.93, 2.73) | 0.0878 |
COPD (vs. none) | 0.855 (0.51, 1.43) | 0.5537 | ||
Diabetes (vs. none) | 1.404 (0.83, 2.37) | 0.2050 | ||
Hypertension (vs. none) | 0.998 (0.59, 1.68) | 0.9954 | ||
Chronic kidney disease (vs. none) | 1.873 (0.99, 3.56) | 0.0550 | ||
TNM stage (vs. stage I/II) | ||||
Stage IIIA | 1.590 (0.70, 3.61) | 0.2679 | 1.328 (0.57, 3.09) | 0.5100 |
Stage IIIB/IIIC | 2.786 (1.27, 6.09) | 0.0103 | 2.117 (0.95, 4.70) | 0.0656 |
Schedule of radiotherapy | ||||
Sequential (vs. concurrent) | 1.252 (0.62, 2.55) | 0.5355 | ||
Regimen (vs. etoposide + cisplatin) | ||||
Etoposide + carboplatin | 1.369 (0.74, 2.52) | 0.3123 | ||
Others | 1.477 (0.46, 4.78) | 0.5147 | ||
Prophylactic cranial irradiation (vs. none) | 0.455 (0.26, 0.79) | 0.0047 | 0.366 (0.20, 0.66) | 0.0008 |
Consolidation chemotherapy (vs. none) | 0.827 (0.49, 1.4) | 0.4810 | ||
High ALI ≥ 44.3 (vs. < 44.3) | 0.470 (0.27, 0.81) | 0.0063 | 0.475 (0.27, 0.84) | 0.0098 |
High LDH (vs. low) | 1.291 (0.75, 2.23) | 0.3578 | ||
